Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Issues
2012 Issues
November Vol 5 No 10
TON - November 2012, Vol 5, No 10
View Digital Edition
Advances in the Treatment of Pancreatic Neuroendocrine Tumors
By
Caroline Helwick
Rare Cancers
TON - November 2012, Vol 5, No 10
— November 21, 2012
Interest in pancreatic neuroendocrine tumors (pNETs) has grown since the recent approval of targeted agents for advanced disease, as was evident by the attendance at several sessions during the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.
1
Read More ›
Noteworthy Numbers
Noteworthy Numbers
TON - November 2012, Vol 5, No 10
— November 21, 2012
In 2012, approximately 1.6 million new cases of cancer will be diagnosed in the United States.
1
A family caregiver, or informal caregiver, will become a necessity for many of the newly diagnosed patients. A family caregiver provides emotional, physical, psychological, and spiritual support to the patient. This, in turn, can take a toll on a caregiver’s own physical, emotional, and even financial health as well. The following statistics provide a glimpse into the characteristics of these unique care providers.
Read More ›
No Increase in Leukemia or Myelodysplastic Syndrome With Adjuvant Chemotherapy for Breast Cancer
By
Audrey Andrews
Breast Cancer
TON - November 2012, Vol 5, No 10
— November 21, 2012
According to a study from the US Oncology Network, breast cancer patients treated with adjuvant chemotherapy have no increased risk for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), at least within the first 3 years of treatment. The study was presented at the American Society of Clinical Oncology 2012 Breast Cancer Symposium by Neelima Denduluri, MD, of Virginia Cancer Specialists.
1
Read More ›
John Theurer Cancer Center - Gold Standard of Care
By
Alice Goodman
Cancer Center Profile
TON - November 2012, Vol 5, No 10
— November 15, 2012
The mission of the John Theurer Cancer Center is to deliver extraordinary care that is multidisciplinary, personalized, innovative, and at the appropriate cost with superior outcomes to the most satisfied patients.
Read More ›
Highlights from the European Society for Medical Oncology
By
Alice Goodman
Conference Correspondent
TON - November 2012, Vol 5, No 10
— November 15, 2012
Oncology experts from all over the globe arrived in Vienna, Austria, to attend the European Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil.
Read More ›
Crizotinib Superior to Chemotherapy in First Head-to-Head Comparison
By
Audrey Andrews
Lung Cancer
TON - November 2012, Vol 5, No 10
— November 15, 2012
In a phase 3 head-to-head comparison trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib proved more effective than standard chemotherapy with pemetrexed or docetaxel as a second-line treatment for non–small cell lung cancer (NSCLC) patients with the ALK genetic abnormality.
Read More ›
Weight Gain After Breast Cancer Treatment Linked to Recurrence
By
Caroline Helwick
Breast Cancer
TON - November 2012, Vol 5, No 10
— November 15, 2012
Early breast cancer patients who gain weight after treatment are at increased risk for breast cancer recurrence, according to an Italian study presented at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria.
Read More ›
From the Editor
From the Editor
TON - November 2012, Vol 5, No 10
— November 15, 2012
In this month’s issue of The Oncology Nurse-APN/PA (TON), we bring you the news from the European Society for Medical Oncology 2012 Congress. Some of the most exciting news came from the update of the PROFILE 1007 trial, with results showing that crizotinib was more effective than standard chemotherapy with pemetrexed or docetaxel as a second-line treatment for non–small cell lung cancer. We also cover the latest treatment information about pancreatic neuroendocrine tumors, which, as one presenter noted, is “not a rare disease any longer.”
Read More ›
Omacetaxine Mepesuccinate Approved to Treat CML
FDA Updates
TON - November 2012, Vol 5, No 10
— November 15, 2012
The US Food and Drug Administration (FDA) has approved omacetaxine mepesuccinate subcutaneous injection (Synribo, Teva Pharmaceutical Industries) for the treatment of adult patients with chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors (TKIs).
Read More ›
Standard of Care for Soft Tissue Carcinoma
Conference Correspondent
TON - November 2012, Vol 5, No 10
— November 15, 2012
Single-agent doxorubicin remains the standard of care as first-line treatment for unresectable or metastatic soft tissue sarcomas, according to results of a phase 3 trial conducted by EORTC and presented at the Presidential Symposium during the ESMO 2012 Congress (Abstract LBA7).
Read More ›
Page 1 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION